Looking at the different pathophysiological events during the lifecycle of the disease, we focus on the underlying mechanism of the disease and embrace state of the art knowledge from partnerships and collaborations to come up with the best solution for the problem.
Alzheimer’s disease (AD) is the most common form of dementia that causes problems with memory, thinking and behavior. It’s not a normal status of aging and is a progressive disease, where dementia symptoms gradually worsen over a number of years. In its early stages, memory loss is mild, but with late-stage AD, individuals lose the ability to carry on a conversation and respond to their environment. AD is the one of the most expensive disease and the only leading cause of death that has exhibited on an increase in mortality rate. Alzheimer's has no current cure, but treatments for symptoms are available and research continues. Although current Alzheimer's treatments cannot stop Alzheimer's from progressing, they can temporarily slow the worsening of dementia symptoms and improve quality of life for those with Alzheimer's and their caregivers.
AMYLOID SOLUTION is focusing on the pathophysiological events related to disease progression and its underlying mechanism to find novel therapeutics.
Our main areas of interest are Amyloid-ß/Tau accumulation, Neuro-immunology, neuronal death and cognitive impairment. BBB penetration technology is our another important area as platform for drug delivery.
Our pipeline can be largely categorized into 2 groups as the targets. Pipelines targeting proteinopathy are expected to reach to commercialization fast. Others targeting glial dysfunction are developing as novel target through novel science.
3F, Institut Pasteur Korea, 16, Daewangpangyo-ro 712beon-gil, Bundang-gu, Seongnam-si, Gyeonggi-do, 13488 Korea
E-mail General email@example.com
We are always looking for companion who share our passion for Alzheimer's Disease.
Come and join us.
Please feel free to contact us via e-mail (firstname.lastname@example.org)